Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
Status:
Active, not recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of MGN1703
that can be given in combination with ipilimumab to patients with advanced tumors. The safety
of this drug combination will also be studied.
This is an investigational study. MGN1703 is not FDA approved or commercially available. It
is currently being used for research purposes only. Ipilimumab is FDA approved and
commercially available for the treatment of unresectable (cannot be removed with surgery) or
metastatic (has spread) melanoma.
Up to 60 participants will be enrolled in this study. All will take part at MD Anderson.